Monday, December 22, 2008

The Invisibleness of Money

Here's a letter to the editor from today's New York Times:
December 22, 2008
Generic Drugs: Let Patients and Doctors Decide
To the Editor:

Your Dec. 10 editorial “(Generic) Drug Resistance” doesn’t mention a critical fact: nearly 7 out of 10 prescriptions in America are now filled with a generic drug.

In New York, pharmaceutical companies cooperated with state officials in fashioning policies for Medicaid and the state employee health plans that have driven generic substitution to more than 90 percent, according to the Department of Health, while protecting patients whose circumstances necessitate brand medications.

The assertion that physicians are “bought off” by pharmaceutical companies insults both the medical profession and the scientists who are working to develop new treatments for patients suffering from chronic and life-threatening illnesses.

America’s pharmaceutical research companies support patients receiving the treatments that are best for them — including brand-name medicines and generics. That said, without innovative medicines there would be no generics.

In the end, these decisions should be made by patients and their doctors, not dictated by pharmaceutical companies or editorial writers.

Ken Johnson
Senior Vice President
Pharmaceutical Research
and Manufacturers of America
Washington, Dec. 15, 2008
The assertion that physicians have often been "bought off" by the drug industry is, alas, all too true. My own specialty, psychiatry, is currently the focus of recurrent revelations about the unseemly conduct of leaders in our field.

What stands out in Mr. Johnson's letter is the absence of any reference to money. It is easy to agree that clinical decisions "should be made by patients and their doctors." But Mr. Johnson avoids the question of who will pay for the conclusions the patient and physician reach.

When drugs are paid for by the individual, preference for a branded product is quite rightly up to the individual. But when drugs are paid for by funds a population puts together for collective benefit - whether via taxes as with Medicare and Medicaid, or via a combination of employer and employee payment as with most private insurance - the collective voice quite properly has a role in allocating the the shared resources.

Note the word "dictated" in Mr. Johnson's final sentence. His rhetoric is subtle. The implication is that any interference with decisions made in the physician-patient dyad would be "dictatorship." But smooth PhRMA rhetoric doesn't print money. Collective funds are limited. Physician and patient autonomy does not, and should not, include the right to commandeer the funds of the commons without any accountability.

Sunday, December 21, 2008

Mayo Clinic Skipped Written Informed Consent - Bravo!

A headline caught my eye this morning - "Mayo Skipped Written Consent."

Before I say more I have to acknowledge a conflict of interest. I admire the Mayo Clinic. I've never been there, but I respect the thoughtfulness of the medical program as reflected in documented outcomes and publications, and the values Mayo has been known for.

Here's the story. George R. Studnicka, a federal prisoner, developed lymphatic cancer. He was referred to the Mayo Clinic for treatment. Mr. Studnicka subsequently claimed that Dr. Daniel Pinheiro operated on him without consent and Dr. Yolanda Garces performed radiation therapy on him, also without consent. (See here for the US District Court Appeal opinion.) Mr. Studnicka's lawyer found no signed informed consent form in the record and complained to the state. An on-site inspection of 12 records showed that none contained signed consent forms.

Mayo wasn't defensive. An administrator told the inspectors "There is no written surgical consent...We don't use them here." The state inspectors reported that Mayo officials told them they "didn't agree with the federal definition of written consent."

Bravo!

The March 2008 issue of the "Proceedings of the Mayo Clinic" had an article on "Medical Informed Consent:General Considerations for Physicians." I don't know whether the timing of the article was coincidental or whether it was meant to present Mayo's philosophy of informed consent. Here's the key summary table from the article:
TABLE 2. Prudent Behaviors of Physicians Engaged in the Process of Medical Informed Consent
* The physician directly involved in the proposed treatment should conduct the informed consent discussion. The discussion should include the treatment, the risks and benefits of treatment, and alternative therapies with associated risks and benefits
* The physician directly involved in the proposed treatment should discuss the most likely outcome with no treatment, on the basis of the best available medical or surgical evidence
* The physician directly involved in the proposed treatment should always discuss the severe risks, such as death, paralysis, loss of cognition, or loss of a limb, even if the probability of occurrences is negligible
* The physician involved in the proposed treatment should always disclose less severe risks that occur frequently. Courts do not place emphasis solely on consequences; they recognize frequency as an important component of risk
* The physician directly involved in the proposed treatment should discuss informed consent in language the patient can understand, and treatment should not proceed until the physician believes the patient understands the risks and benefits and has made a rational decision
* The physician directly involved in the proposed treatment must understand that the medical consent form is not medical consent; it represents evidence that the consent process occurred. The dialogue between the patient and physician is the essence of the consent process (emphasis added)
* The physician directly involved in the proposed treatment should document all patient-imposed restrictions in the medical record and the discussion with the patient about how the restrictions limit the physician’s ability to provide standard medical care...
* When physicians and patients take medical informed consent seriously, the patient-physician relationship becomes a partnership, with shared authority, decision making, and responsibility for outcomes The physician directly involved in the proposed treatment can enhance the informed consent process through appropriate use of additional learning materials, such as pamphlets and video, and through involvement of support staff, such as physician assistants, in providing information that can be discussed by the responsible physician
In my view this represents an exemplary approach to informed consent. The recurrent reference to "the physician directly involved..." and the concluding bullet correctly portray informed consent as a crucial clinical process between clinician and patient, not as a bureaucratic event between pen and paper. Sadly, medical students I've taught have described being sent onto the hospital ward to "consent the patient" - i.e., get the patient to sign a document, which demeans informed consent and invites the student to become cynical.

Apparently, and not surprisingly, the level of documentation in Mayo charts was variable. That's not acceptable. And apparently federal regulations require signed forms in certain circumstances. Mayo agreed to implement a written consent form. I hope the Clinic does this in the clinically sensitive spirit embodied in the passage I quoted.

Wednesday, December 17, 2008

Health Care Rights in India and the U.S.

In yesterday's post on "Drug Marketing in Mumbai" I mentioned that I'm reading ethics literature from India in preparation for a visit I'll be making soon.

In the most recent issue of the Indian Journal of Medical Ethics, Dr. Helen Sheehan from the South Asia Studies Department at the University of Pennsylvania has a fascinating article on "Cancer, access to investigational drugs, and patient rights in the USA and India."

Dr. Sheehan tells a story from the U.S. (the Abigail Alliance case, which I discussed in "Access to Experimental Drugs - the Supreme Court Gets it Right") and a story from India (a cancer drug trial carried out at the Regional Cancer Center in Thiruvanathapuram in Kerala).

What's most striking in the story is that the rights at stake are polar opposites. Interestingly, both situations involve Johns Hopkins.

The Abigail Alliance case was brought on behalf of Abigail Burroughs, a young woman who contracted a rare head and neck cancer that did not respond to standard treatment. Her Johns Hopkins physician wanted to give her an experimental medication, not yet approved by the FDA. The legal action claimed a right for dying patients to have access to experimental drugs. The drug was not made available. Abigail died in 2001. The drug was subsequently approved by the FDA.

The posthumous appeal claimed a constitutional right to the drug, based on the fifth amendment guarantee that no person shall “be deprived of life, liberty, or property, without due process of law.” Patients in “last chance” situations, when standard treatment offers no hope – are facing death. The Abagail Alliance argued that by not facilitating access to drugs that have passed through Phase 1 trials, the FDA is depriving them of the right to opt for a potentially life-saving intervention. The District of Columbia Circuit Court ruled against the Alliance.

The situation at the Regional Cancer Center in Kerala involved trial of an experimental drug on 27 oral cancer patients from November 1999 to April 2000. The agent had only been tested in mice. Without approval from any IRB, a scientist from Johns Hopkins contracted with the Regional Cancer Center and brought the drug to India. In July 2001 a physician at the Regional Cancer Center blew the whistle on the study, claiming that no approval had been given and that the informed consent process was a sham. Johns Hopkins conducted its own investigation and concluded:
* The scientist was negligent for failing to submit a proposal for the clinical trial to a Johns Hopkins University institutional review board. Under university policy and federally mandated procedures, faculty experiments involving human subjects must have prior IRB approval, whether conducted in the United States or abroad.

* The trial did not meet Johns Hopkins standards for research with human subjects. For example, the committee found there was inadequate safety testing of the drugs in animals before they were injected into human patients. The committee also said that consent forms used to recruit patients for the study were inadequate.

* The scientist carried drugs used in the study to India without either an "investigative new drug" approval from the Food and Drug Administration or explicit FDA export permission.

* The scientist, without authority, signed several versions of a document committing the university to collaboration with the RCC.
In the U.S., the Abigail Alliance claimed (unsuccessfully) that the FDA regulations were too strict and abrogated Abigail's rights by preventing her and her physicians from protecting her against avoidable death. In India critics concluded that the Regional Cancer Center was too lax in its oversight of research, and that the drug trial abrogated participants' rights to adequate protection.

It isn't surprising that a country with strict research regulations (the U.S.) pushes drug research to sites where the regulation is more lax (such as India).
A New England Journal article discusses the risks to India as "A New Colonialism."

I hope we are in the process of seeing a global re-equilibration with regard to "rights" in health care. In the U.S. our expectations are excessive - as evidenced by our belief that we have a right to anything we or our doctors hope might provide benefit. In India, at least as seen by an outsider, expectations for what each individual deserves are too low, as evidenced by the way poor patients at the Regional Cancer Center were herded into a study. The disputed drug trial in India reflects the dark side of both countries - U.S. entitlement to join in the exploiting of poor citizens in India.

We owe thanks to the whistleblowers and journalists who give both countries opportunity to look in the mirror and see our failings.

Tuesday, December 16, 2008

Drug Marketing in Mumbai

I'll be in India for a month in 2009. One purpose of the trip is to learn about medical ethics education, ethics committees and the broad landscape of health system ethics, so I've been reading ethics literature from India itself. An article on "Drug promotional practices in Mumbai: a qualitative study" in the Indian Journal of Medical Ethics caught my attention.

The authors interviewed 15 senior executives from multinational (4) and Indian (11) drug companies, 25 pharmacists - 5 wholesalers and 20 retailers (5 attached to large hospitals and 5 stand alone shops each in rich, middle class and slum neighborhoods), 26 medical representatives from Indian (9) and multinational (27) companies, and 25 physicians - 13 GPs and 12 specialists who practiced in rich, middle class and slum neighborhoods.

Here are some excerpts from the article - with my comments in italics:
1. Information and brand reminders.
"Doctors stated that they received information on new drugs primarily through visits by MRs who use flip charts for this purpose. 'These flipcharts show the benefits of their drugs over the drugs of other companies. They also provide results of studies carried out by them on the drug's efficacy.' (general practitioner in slum)

According to the doctors, MRs rarely mentioned drug interactions and adverse reactions but they were otherwise generally satisfied with the information provided and accepted the MR's role. 'Everything is told in a precise way... medical representatives are well versed with their products and quite capable of answering the doctor's questions.' (senior general practitioner in middle-class neighbourhood)"

I saw this same system in action in 1989 when I spent a day with a psychiatrist in a public clinic. He let medical representatives join him when patients and their families (no one came in alone) were in the consulting room. As described in the 2007 article, the MRs pulled flip charts out of their valises and used them to demonstrate the virtues of their products.

"The doctors did state that MRs took up time that could be spent attending to patients and MRs were aware of this. "Doctors always perceive MRs' visits as an intrusion. Every minute taken up by the MR is time which could have been spent seeing patients and making money in the clinic. Often, MRs queue up early in the morning for doctors who allow only the first three MRs to see them." (from focus group discussion with medical representatives)"
The physicians I've spent time with in the public sector were treated like Gods. After the appointment patients touched the physician's shoe as a gesture of respect. It sounds as if the medical representatives had to come as supplicants in a similar fashion.
2. Incentives.
"Some MRs said incentives had become less cost-effective over the years as each company tried to offer more expensive gifts than the others. Incentives did not work to build a doctors' loyalty to a particular brand as all companies offered incentives. So they were now increasingly based on the prescriptions generated. Two doctors practising in slum areas showed printed handouts from a drug manufacturer giving targets and incentives to meet them. They were offered a cell phone handset for prescribing 1,000 tablets, an air cooler for prescribing 5,000 tablets and a motorcycle after 10,000 tablets were prescribed."

This direct "payment" for the number of pills of prescribed is a form of fee splitting. The practice should be seen as unambiguously unethical. There's no way a patient could, or should, trust the prescribing practices of a physician who receives direct payments for prescribing a specific medication.

"Another promotional practice was to finance educational programmes and conferences. Individual doctors' travel, stay and conference fees were also paid for by drug companies. Most doctors had no objection to such support and said they could not otherwise afford these meetings that they described as informative. A small minority felt that the lack of transparency in the funding of medical programmes by drug companies was unacceptable. Nearly half the doctors and all the MRs felt that over the past decade conferences had moved out academic college auditoria to five-star hotels which served lavish cocktail dinners, all with an accompanying increase in budgets."

All of the physicians I know who work in the public sector in India have difficulty paying for educational programs and conferences. If pharmaceutical companies gave money to a central body that administered a fund independently the practice would be acceptable. But paying for specified conferences where slanted presentations may be given is marketing, not education. And while we should not begrudge five-star hotel dinners or overseas conferences for hard working physicians - they deserve R&R - for drug companies give vacations and motorcycles it creates a clear conflict of interest for the physician.

"Drug companies stated that funding medical conferences had become less cost-effective; they suggested that doctors as a group had begun to pressurise pharmaceutical companies into financing their associations' programmes and would even boycott drug companies that did not give in to their demands. 'Things have got to such a stage now with doctors actually demanding sponsorship from companies. This year (an Indian drug company) had zero participation in (a specialist association's) conference. The company is now feeling the heat in the form of infrequent prescriptions.'(senior executive of an Indian drug company)"

This form of frontier capitalism would be funny if the problem weren't so serious. Drug companies give motorcycles for prescribing 10,000 pills. Professional societies boycott medications if the drug company doesn't pay up for their conferences. This is reciprocal bribery and strongarming!
3. Trade Practices.
"Retail chemists said that the multiplicity of brands made it difficult for them to stock all drugs and they risked being left with unsold stock. They therefore stocked the drugs of those companies which were promoted well both with the chemists as well as the doctors. Hence, it made sense for MRs to be consistent in promotion with doctors as well as chemists.

It was also reported by drug companies that chemists associations [demanded]...a charge of Rs 5,000 to Rs 10,000 to the association of wholesale chemists to stock a new product. Drug companies also gave other incentives to chemists to stock their own products."

Paying physicians to prescribe their medications and pharmacies to stock them has the elegance of a military pincer attack! All that is lacking is getting the patients to ask for the product.

"...Screening camps were used to influence public knowledge about a disease and also expand the market for the drug for that disease."

With direct outreach to the public, all the marketing bases are covered - patients, pharmacies and physicians. Since few medications are paid for by insurance, that sector, which would be important in the U.S., is currently not central in India.
All of the issues described in Mumbai are present in the U.S., but in India the pharmaceutical practices are more brazen. Federal and state regulatory capacity is significantly less in India than in the U.S. Perhaps more important, organizations - medical schools, hospitals, medical societies, and more - currently have less capacity to push back against commercial forces than comparable institutions in the U.S.

But the Indian media is sinking its teeth into the issue of commercial corruption of medical decision making (see, for example, "Are your drugs boosting your doctor's lifestyle?" in yesterday's Times of India here). The same ethical drama is playing out globally, just with different timing.

Monday, December 15, 2008

Why Ethics Has a Bad Name

Here's an excerpt from an article about Illinois Governor Blagojevich I read over coffee in this morning's New York Times:
The moment could not have been more welcoming for a Democrat. Gov. George Ryan, a Republican who was by then engulfed in a corruption scandal, did not run for re-election, and the Republican who did had a long record of public service but an unfortunate last name: Ryan.

Mr. Blagojevich focused his campaign on pledges of reform and clean government, and won. Once in office, even amid accusations of campaign donations being exchanged for state jobs, Mr. Blagojevich continued to promote himself as a lonely fighter against the gargantuan pressures of lobbyists and lawmakers — pressing for tougher ethics laws, appointing inspectors general and sending state employees to “ethics training.”
In an earlier posting about "A Ridiculous Use of Medical Ethics Teaching" I speculated about why a state ethics board ordered a physician whose multiple offenses suggested incorrigibility to take an ethics course. The three possibilities I came up with were cynicism (avoid meaningful action by appearing to do something), optimism (the multiple offender means well - an ethics course will show him the true path) and magic (like divine intervention, the ethics class will pierce the miscreant's evil self and bring about transformation).

Governor Blagojevich, who is now the toast of late night comedy shows, provides a fourth reason ethics can have a bad name - duplicity. This is the technique the hungry wolf used in hope of eating Little Red Riding Hood. Disguising himself as the kindly grandmother is like the Illinois governor presenting himself as the candidate of reform.

Ethics education and ethics committees can be enormously valuable, but only as a support for the objectives set by ethical leaders. As grandma probably told Little Red Riding Hood - actions speak louder than words.

Thursday, December 11, 2008

A Mental Health Tragedy

At 8:00 PM on Friday January 11, 2008, Marci Thibault came to her twin sister's home to pick up her 4 year old nephew Shane and 5 year old niece Kaleigh for a sleepover at her own home in Bellingham MA. On the way home she pulled her car into the median of the highway, undressed herself and the children, and carried the children into the oncoming traffic. All three were killed.

Four months earlier Thibault had been treated at McLean Hospital for a psychotic episode. She was discharged after six days with medication and a referral for outpatient treatment. Between her discharge and her death she was said to be "95 percent back to her old self."

On her way to her sister's home Marci Thibault came to the attention of the state police. She apparently drove into the median area at full speed. When a motorist stopped to offer help she began to punch him. State police came to the site and questioned her. She told them she was having "a debate between good and evil." The troopers considered committing her to a psychiatric hospital, but she calmed down, and they concluded they did not have enough evidence to do so.

By the time Marci arrived at her sister and brother in law's home, however, "she was acting like the normal Marci I knew all my life," her twin sister Danielle Lambert, a pediatric nurse practitioner, reported.

In the aftermath of the tragic event, Danielle and Ken Lambert, Kaleigh and Shane's parents, have started a nonprofit group "to improve the mental health system by educating the public and promoting practical solutions."

I'm writing about this story on a blog devoted to health system ethics for two reasons.

First, the way Danielle and Ken Lambert have channeled their grief is ethically admirable. By devoting themselves to "prevent[ing]similar incidents from occurring by improving society's understanding and management of mental health issues" they are transforming private tragedy into public benevolence. And, the fact that they portray Marci Thibault, the agent of their childrens' death, as a victim of mental illness and not as a perpetrator, shows an admirable capacity for not blunting grief through blame.

Second, the excellent Boston Globe article from which I learned about this tragic event, is unusually clear about the ethical trade off between public protection and civil liberties:
Dr. Alberto M. Goldwaser, a forensic psychiatrist who teaches at New York University's medical school, said it is understandable that the Lamberts are second-guessing the State Police and McLean. But he said the couple's criticisms are probably unrealistic.

"Right now, we know the police should have taken her to a hospital, and then this tragic event wouldn't have happened. But that's in hindsight," said Goldwaser, who is not involved in the case. "So, yeah, [Thibault] was peculiar. We're talking about taking her liberties, taking her freedom"...

Thibault's husband, Michael, an EMC Corp. employee who met his wife at Bellingham High School, said it might be a good idea for police to have access to a database of individuals who had been committed to psychiatric hospitals, despite the inherent privacy concerns. He said the State Police "had Marci in their hands on the way up" to New Hampshire.

But Dr. Mark Goldblatt, a Cambridge psychiatrist and president of the New England chapter of the American Foundation for Suicide Prevention, said Americans are ambivalent about how to respond to people with mental illness.

"Society wants it both ways," he said. "We want to have complete freedom and liberty and not be restrained by government, not have people's names in databases. And at the same time, we want to control people who live a certain way with mental illness. It's hard to have both."
The Boston Globe deserves gratitude for the kind of journalism that contributes to public understanding of complex ethical issues. And, most notably, Danielle and Ken Lambert deserve admiration and respect for their efforts to transform private grief into public altruism.

Tuesday, December 9, 2008

MRI and CT - the Curse of Incidentalomas

In 2001, 225 leading general internists were asked to rank 30 medical innovations in terms of their importance for patient care (see Health Affairs article here). By a large margin the group judged magnetic resonance imaging (MRI) and computed tomography (CT) scanning to be the most important. For physicians like me who entered medicine before the new imaging techniques were developed, the information MRI and CT provide seems miraculous!

But as physicians know all-too-well and as an excellent New York Times article by Gina Kolata today describes especially clearly - as scans rapidly improve, the frequency of "incidentalomas" increases just as fast.

Incidentalomas are scan findings that get labeled "abnormal" but actually have no clinical significance and are not causing a problem for the patient. The Kolata article describes Cheryl Weinstein, a healthy 64 year old with knee pain. Here's her story:
When she started looking up her symptoms on the Internet, she decided she probably had a meniscus tear. “I was very forceful in asking for an M.R.I.,” she said.

And when the scan showed that her meniscus was torn, she went to a surgeon expecting an operation.

He X-rayed her knee and told her she had arthritis. Then, Mrs. Weinstein said, the surgeon looked at her and said, “Let me get this straight. Are you here for a knee replacement?”

She said no, of course not. She skis, she does aerobics, she was nowhere near ready for something so drastic.

Then the surgeon told her that there was no point in repairing her meniscus because that was not her problem. And if he repaired the cartilage, her arthritic bones would just grind it down again.

For now, Mrs. Weinstein says she is finished with her medical odyssey.
Luckily the surgeon Mrs. Weinstein saw knew that cartilage tears are as common in people with arthritis of the knee who have no pain as they are for people with knee arthritis who do have pain. Otherwise she might have had an unnecessary operation. She would have risked complications for no potential upside gain. And all of those whose funds created the insurance pool that paid for the surgery would have wasted money.

The situation is much the same with herniated discs. Kolata reports on research demonstrating that routine scans for back pain do not improve outcomes. And the large number of "false positives" (scans interpreted as abnormal where the "abnormal" findings are not causing a problem) create psychological distress for the patients and may lead to unnecessary and potentially harmful tests and procedures.

MRI and CT are spectacular medical advances, but like everything in medicine they have potentially negative side effects. A substantial number of scans done in the U.S. should not be done. (Estimates vary, but all the estimates I've seen are more than 10%.) Unnecessary scans cause clinical and economic harm. Gina Kolata's article can be useful in public education - to help us better understand the limits of technology and the need to tolerate uncertainty.